The Capitol LedgerEvery move in Congress, on the record
HomeBillsRecordsLedger AI

The Capitol Ledger

Built from the Congressional Record and Congress.gov. Every summary links to its source.

AboutFAQFeedbackTerms of ServicePrivacy Policy
Follow us onlineInstagram

Summaries are AI-generated from primary sources. Verify anything important against the original record.

The Capitol Ledger

Built from the Congressional Record and Congress.gov. Every summary links to its source.

The projectAboutFAQFeedback
LegalTerms of ServicePrivacy Policy
Follow us onlineInstagram

Summaries are AI-generated from primary sources. Verify anything important against the original record.

All bills
S. 4940·119th Congress·Introduced Jun 24, 2026

Specialized Infant Formula Protection Act

IntroducedAgriculture and FoodMajor
View bill text
Sponsor
Sen. Ernst, Joni [R-IA]
Committees
Judiciary Committee (primary)
Last action
Jun 24, 2026

Bottom line

The bill shifts jurisdiction for product liability lawsuits concerning specialized preterm infant formula from state to federal courts, aiming to standardize legal remedies and prevent perceived 'jurisdiction shopping' that proponents argue could threaten formula supply.

What it actually does

This bill grants federal district courts original jurisdiction over civil actions alleging injury caused by preterm infant formula regulated by the Food and Drug Administration, provided there is diversity of citizenship. It also allows any defendant to remove such cases from state to federal court without the consent of all defendants. The provisions apply retroactively to cases pending or filed on or after the enactment date.

Proponents argue

Proponents argue that this legislation is essential to protect the domestic supply of specialized infant formula for vulnerable preterm babies. They contend that 'procedural gamesmanship' and 'court shopping' in state courts create an unpredictable legal environment that could lead to manufacturers limiting production or exiting the market, thereby jeopardizing access to critical nutrition. Federal jurisdiction, they assert, will ensure uniform judicial remedies and stability.

Opponents contend

Opponents might argue that this bill strips state courts of their traditional and appropriate jurisdiction over product liability claims, potentially making it more difficult and costly for families of injured infants to seek justice. They may contend that it prioritizes the interests of manufacturers over those of consumers and that the retroactive application could disrupt ongoing legal proceedings and undermine established legal principles.

The bill is exceptionally short and clearly written, making it very accessible for a quick read and understanding of its core provisions.

Section 2

Purpose and Findings

prominently featuredstraightforward

This section outlines the legislative intent and the factual basis for the bill. It states the purpose is to ensure the continued availability of specialized infant formula for preterm babies. It includes findings that nearly 380,000 infants are born preterm annually, depend on FDA-regulated formula, and that 'procedural gamesmanship' in state courts may limit supply, necessitating federal court jurisdiction for uniform remedies.

GroupImpactMechanismScale
GroupPreterm infants and their familiesImpactIndirect benefit through ensuring formula availability (proponents' view)MechanismLegislative declaration of intent to protect supplyScaleNational
GroupInfant formula manufacturersImpactBenefit from stated legislative support for stable supply chainMechanismLegislative declaration of intentScaleIndustry-wide

Supporters argue

Supporters argue that clearly stating the purpose and findings provides a strong rationale for the bill, highlighting the critical need to protect the supply of specialized formula for vulnerable infants and justifying the federal intervention.

Critics contend

Critics may argue that the findings overstate the threat to formula supply from state court litigation and serve primarily to create a narrative that favors manufacturers, potentially downplaying the importance of state-level consumer protections.

Tradeoffs

The section balances the perceived need to protect a critical supply chain against potential implications for state judicial authority and consumer recourse.

Section 3

Federal Jurisdiction Over Certain Infant Formula Actions

prominently featuredmoderately complex

This provision amends Title 28, United States Code, Section 1332, to grant federal district courts original jurisdiction over civil actions related to alleged injuries caused by FDA-regulated preterm infant formula. This new jurisdiction applies if there is diversity of citizenship between any plaintiff and any defendant, or between a plaintiff and a foreign defendant. It explicitly states that this does not limit the authority of the judicial panel on multidistrict litigation.

Section 4

Removal of Infant Formula Actions

prominently featuredmoderately complex

This section amends Title 28, United States Code, Section 1441, to allow any defendant to remove a civil action from a state court to a federal district court if that action falls under the new federal jurisdiction established in Section 3. Crucially, this removal can occur 'without the consent of all defendants,' which is a departure from the general rule requiring unanimous consent for removal in many civil actions.

Section 5

Applicability of the Act

mentioned in summarystraightforward

This section specifies that the Act, and the amendments it makes, will apply to any civil action that is pending on the date of its enactment, or any action filed on or after that date. It explicitly states that this applicability is 'without regard to the State court filing date,' meaning it can retroactively pull existing state court cases into federal jurisdiction.

About this analysis. AI-Generated from the official bill text and available committee reports. Gaps in available data are noted explicitly. Verify important details with the official Congress.gov record.

On this page

  • Executive summary
  • Key provisions
  • Follow the money
  • Critical analysis
  • Questions to ask
  • Implementation
  • Political analysis
Ask Ledger AI about this